On the assessment and impact of liver fibrosis in patients with chronic Hepatitis C
Full text
Related documents
In the NORDynamIC study with 354 peg-IFNα2a and RBV treated chronic HCV genotype 2 or 3 infected patients, we were able to demonstrate that SNPs in ITPA reducing the activity
2020 Impact of Genetic V ariants in Inosine T riphosphate Pyrophosphatase and Interferon- λ4 on Natur al History , Treatment Response and Ribavirin Pharmacology in Hepatitis C
genetic variants of PNPLA3, IL28B and ITPA, on liver disease severity and treatment outcome in HCV genotype 2 and 3 infected patients treated with pegylated interferon and
[r]
Previous studies have shown that grade of inflammation as well as stage of fibrosis in 1-year protocol biopsies of the liver graft to be predictive of fibrosis
Patients with chronic HCV genotype 2/3 infection who were non-responsive to combination therapy had significantly lower plasma concentrations of interferon in
Approximately 80% of patients infected with HCV genotypes 2 or 3 achieve a sustained virological response (SVR), following 24 weeks of therapy with ribavirin
To further investigate the mechanism of restriction, we used transcriptional profiling of Huh-7.5 cell lines ectopically expressing murine restriction factors (mCd302, mCr1l,